Form 8-K

 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 


 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): October 23, 2003

 


 

RESPIRONICS, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware

(State or Other

Jurisdiction of Incorporation)

 

000-16723

(Commission

File Number)

 

25-1304989

(I.R.S. Employer

Identification Number)

 

 

1010 Murry Ridge Lane

Murrysville, Pennsylvania

(Address of Principal Executive Offices)

     

15668-8525

(Zip Code)

 

 

724-387-5200

(Registrant’s telephone number, including area code)

 


 


TABLE OF CONTENTS

 

 

     Page

Item 9. REGULATION FD DISCLOSURE.

   2

SIGNATURES

   3

INDEX TO EXHIBITS

   4


 

Item 9.   REGULATION FD DISCLOSURE.

 

The following information is furnished pursuant to Item 12, “Disclosure of Results of Operations and Financial Condition.”

 

On October 23, 2003, Respironics, Inc. issued a press release announcing its financial results for the three months ended September 30, 2003. A copy of the press release is attached hereto as Exhibit 99.

 

Exhibits

 

99    Press release dated October 23, 2003 issued by Respironics, Inc.

 

 

 

2


 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

RESPIRONICS, INC.
By:   /s/    Daniel J. Bevevino
 
   

Daniel J. Bevevino

Vice President, and Chief Financial and

Principal Accounting Officer

 

Dated: October 23, 2003

 

 

3


 

I NDEX TO EXHIBITS

 

Exhibit No.

  

Description


99

   Press release, dated October 23, 2003, issued by Respironics, Inc.

 

 

4